I have a feeling that after we get the CE Mark approval the next 2 or 3 days we will trade with high volume and might get up to $2 but after that it will be like today. We will resort back to low volume days and probably drift back lower.
The good thing is they are ready to start selling Neutrolin and there are a lot of what ifs that can happen. Partnership, buyout, U.S. trial, Tauropharm lawsuit...etc..
Would it take that much to make these guys profitable? Could it happen this year?
I guess we'll see. I continue to look at enterprise value and even @ $2 that would still be a very modest valuation given the size of the potential sales. Remember, there is not only Dialysis but also expansion into oncology and other CV catheter settings. Could it be sold? Sure. That said, my bet remains that these guys are given enough leash by Elliot and others to make a reasonable play for Europe. I believe partnering is more likely in the U.S. given the need to run a trial.
Not sure re: IP issue. Maybe the Tauropharm guys come to the table too late. Post approval, the clock is on the side of Cormedix. At some point I believe they will the rhetorical "What's the point of a settlement?" especially in light of potential claw-backs. We'll see. First things first--let's see what an approval does for the valuation of this little company.